Bracco Loses U.S. Trade Case Against Jubilant Over Imaging Agent

December 2, 2019, 10:11 PM UTC

Bracco Diagnostics patents for a radioisotope infusion system used in heart-imaging procedures are invalid, U.S. International Trade Commission said in a notice posted on its website.

  • Commission affirms, with modifications, judge’s finding of invalidity and terminated the investigation with a finding of no violation by Jubilant Life Sciences
  • Bracco claimed Jubilant’s Ruby imaging agent infringes three patents for strontium-rubidium radioisotope infusion systems
  • Bracco sought an order to block imports of Jubilant DraxImage systems made in Canada
  • Patents cover a computer-controlled medical device, plus the method of making it and ways to use it to infuse a patient with radioisotope rubidium-82 ...

Learn more about Bloomberg Law or Log In to keep reading:

See Breaking News in Context

Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.

Already a subscriber?

Log in to keep reading or access research tools and resources.